sciencePipeline Spotlight

CagriSema

Novo Nordisk's next-generation combination: cagrilintide (a long-acting amylin analog) paired with semaglutide in a single weekly injection.

CagriSema is Novo Nordisk's attempt to extend semaglutide's reach without leaving the GLP-1 platform. It combines two molecules in one once-weekly subcutaneous injection: cagrilintide, a long-acting analog of the gut hormone amylin, and semaglutide, the GLP-1 receptor agonist already familiar from Ozempic, Wegovy, and Rybelsus.

CagriSema is not yet FDA-approved. The Phase 3 program (REDEFINE) is still reading out, and trial data so far has been mixed — early results landed below some of the more optimistic pre-trial expectations. Dosing, label, and headline efficacy may change before launch. Treat anything in this article as a snapshot of where the science stood at the time of writing.

For patients tracking what comes after Wegovy, CagriSema is the next Novo Nordisk candidate to watch. Here is the practical context.

What it is

CagriSema is a once-weekly subcutaneous injection in a single pen device. Each dose delivers two active drugs: cagrilintide and semaglutide. Cagrilintide is a once-weekly amylin analog (amylin is a hormone co-released with insulin from pancreatic beta cells, with effects on satiety and gastric emptying). Semaglutide is the same GLP-1 receptor agonist as Wegovy.

The hypothesis behind the combination is that amylin agonism and GLP-1 agonism work through complementary pathways. Amylin slows gastric emptying and signals satiety to the brainstem; GLP-1 hits parallel central and peripheral pathways. Combining them in one molecule (or, in this case, one mixed injection) could produce additive or synergistic weight loss compared with either alone.

Phase 2 data was encouraging. Phase 3 REDEFINE-1 results came in lower than some pre-trial expectations: trial mean weight loss landed below the highest projections, though still meaningful compared with semaglutide alone. The full Phase 3 program will give a clearer picture of where CagriSema sits relative to Wegovy and Zepbound.

How it compares

Versus Wegovy (semaglutide alone), CagriSema is expected to produce additional weight loss because of the added cagrilintide component. Early Phase 3 data confirmed an advantage, though the size of that advantage came in below pre-trial expectations and below what some had hoped would close the gap with tirzepatide.

Versus Zepbound (tirzepatide), CagriSema sits in roughly the same conceptual category — a combination drug aimed at deeper weight loss than single-receptor agonists. Whether it actually matches or beats tirzepatide on weight loss in head-to-head conditions is unresolved. Cross-trial comparison favors tirzepatide on the early Phase 3 numbers, but a direct trial would settle it.

Side-effect signals so far look broadly consistent with GLP-1-class drugs: gastrointestinal effects during titration, with some additional considerations from the amylin component. The full safety picture, including discontinuation rates, will come from Phase 3.

FDA approval timing depends on how REDEFINE finishes reading out and what Novo Nordisk files. Most outside analysts expect a 2026 to 2027 window if the program continues, with chronic weight management as the most likely first indication.

What to know if you're considering it

Watching CagriSema before approval

hourglass_top

Not yet available

CagriSema is in Phase 3. It is not FDA-approved, not commercially sold, and not legally compoundable. Any product sold under this name outside an authorized trial is unverified.

fact_check

Trial data has surprised on the downside

Early Phase 3 results came in below some pre-trial expectations. The drug appears to beat semaglutide alone, but by less than some analysts had projected.

compare_arrows

It won't replace semaglutide for everyone

If CagriSema launches, it will be an additional option, not a successor to Wegovy. Cost, insurance handling, and patient response will determine who switches.

Common questions

Common Concerns

When will CagriSema be available?expand_more

Earliest realistic FDA approval is 2026 to 2027, dependent on Phase 3 results and Novo Nordisk's filing timeline. After approval, launch, payer coverage, and pharmacy availability each add lead time. Specific dates remain speculative until the company files.

Will CagriSema beat Wegovy?expand_more

On weight loss, the early Phase 3 data suggests CagriSema produces more weight loss than semaglutide alone — but by a smaller margin than some pre-trial projections. The advantage exists; the size of it is the question.

Is CagriSema the same as cagrilintide?expand_more

No. CagriSema is the combination of cagrilintide and semaglutide in one weekly injection. Cagrilintide alone is a separate molecule in its own development program.

Can I get CagriSema from a compounding pharmacy?expand_more

No. Cagrilintide is not FDA-approved as a standalone or in combination, and CagriSema cannot be legally compounded. Anything sold under that name outside a clinical trial is unverified and unsafe.

Keep exploring

Browse all GLP-1 guides.